Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-03-01 DOI:10.21873/anticanres.17505

Leticia Iglesias, Rocío Vílchez, Santiago Aguín, Ramón García, Carolina Pena, Alberto Carral, Gerardo Huidobro, Aurea Molina, Jesús García Gómez, Marta Covela, Marinha Costa, Ana Medina

{"title":"Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study.","authors":"Leticia Iglesias, Rocío Vílchez, Santiago Aguín, Ramón García, Carolina Pena, Alberto Carral, Gerardo Huidobro, Aurea Molina, Jesús García Gómez, Marta Covela, Marinha Costa, Ana Medina","doi":"10.21873/anticanres.17505","DOIUrl":null,"url":null,"abstract":"Background/aim: Real-world evidence regarding the use of nivolumab in metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is limited. This study aimed to describe the clinical characteristics, outcomes, and safety of nivolumab in R/M SCCHN patients treated in routine clinical practice.Patients and methods: This retrospective, observational study evaluated the efficacy/safety of nivolumab in 116 patients with R/M SCCHN treated at nine centers within the Galician Group of Head and Neck Cancer health network between 2017 and 2019.Results: Basal characteristics of patients included a median age of 60 years, ECOG performance status -2 (14%) and -3 (1%) and a first diagnosis of stage IV a/b/c (74%). Nivolumab was used as first line, second line, and third line therapy in 17%, 66%, and 17% of patients, respectively. After a median follow-up of 14 months (range=1-69 months), the median progression-free survival was 2.30 months (95%CI=1.45-3.14) and the median overall survival was 8.1 months (95%CI=5.93-10.23). Outcomes were better when nivolumab was administered earlier in treatment course. Grade 3/4 adverse events were observed in 21.27% of patients.Conclusion: These findings support the efficacy and safety of nivolumab in the real-world treatment of R/M SCCHN.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1181-1191"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17505","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Real-world evidence regarding the use of nivolumab in metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is limited. This study aimed to describe the clinical characteristics, outcomes, and safety of nivolumab in R/M SCCHN patients treated in routine clinical practice.

Patients and methods: This retrospective, observational study evaluated the efficacy/safety of nivolumab in 116 patients with R/M SCCHN treated at nine centers within the Galician Group of Head and Neck Cancer health network between 2017 and 2019.

Results: Basal characteristics of patients included a median age of 60 years, ECOG performance status -2 (14%) and -3 (1%) and a first diagnosis of stage IV a/b/c (74%). Nivolumab was used as first line, second line, and third line therapy in 17%, 66%, and 17% of patients, respectively. After a median follow-up of 14 months (range=1-69 months), the median progression-free survival was 2.30 months (95%CI=1.45-3.14) and the median overall survival was 8.1 months (95%CI=5.93-10.23). Outcomes were better when nivolumab was administered earlier in treatment course. Grade 3/4 adverse events were observed in 21.27% of patients.

Conclusion: These findings support the efficacy and safety of nivolumab in the real-world treatment of R/M SCCHN.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.